Vijay Pande Steps Down from a16z Bio + Health

Vijay Pande to Step Down from Andreessen Horowitz’s a16z Bio + Health

Vijay Pande, a general partner at Andreessen Horowitz and the founder of the firm’s a16z Bio + Health division, has announced his departure from his current position.

Established in 2014, a16z Bio + Health has successfully raised capital through four funds to date.

Fundraising Shifts at a16z Bio + Health

Notably, a $1.5 billion fund was finalized in 2022. However, current efforts are focused on securing a $750 million fifth fund, as reported by The Wall Street Journal.

In January, a significant development was announced: a16z Bio + Health will independently administer a $500 million fund specifically dedicated to biotech investments, with funding provided by pharmaceutical leader Eli Lilly.

Investment Focus and Portfolio

The firm concentrates its investments on digital health startups and ventures operating at the convergence of artificial intelligence, computational methods, and biological sciences.

Pande’s investment portfolio includes prominent companies such as Devoted Health, a provider of individualized medical plans, Function Health, a startup specializing in personalized lab testing, and Freenome, a company focused on cancer detection via blood analysis.

Prior Experience

Prior to his tenure at Andreessen Horowitz, Pande held a professorship at Stanford University, encompassing the fields of chemistry, structural biology, and computer science.